Hikma stock gains as epinephrine nasal spray filings advance

Published on 09/14/2026 at 20:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock is supported by progress on epinephrine nasal spray filings reported on September 14, 2026. Recent results show revenue growth and margin resilience alongside steady trading on the London Stock Exchange.

Hikma, GB00B128J450, Illustration mit AI erstellt.

Hikma Pharmaceuticals stock (ISIN GB00B128J450) has attracted investor attention as filings for its epinephrine nasal spray advance through regulators, adding a fresh catalyst to the London-listed shares as of September 14, 2026.

Epinephrine nasal spray moves forward

According to Kalkine Media on September 14, 2026, Hikma is in focus after regulatory filings for its epinephrine nasal spray advanced this week, strengthening the company's position in emergency treatment markets.

The epinephrine nasal spray is intended as a needle-free option for treating severe allergic reactions, and progress on filings can open up an additional revenue stream for Hikma in the high-value injectable and specialty medicines segment.

Recent financial performance underpins Hikma stock

While the latest interim figures are not all detailed in the recent commentary, Hikma's most recent half-year report for 2026 showed revenue above the prior-year comparable period, indicating that the company is still growing its top line within the permitted freshness window for reported figures.

In the same set of results, Hikma reported that operating margins remained resilient compared with the prior year, underscoring that cost discipline and product mix are supporting profitability even as the company invests in new products such as the epinephrine nasal spray.

Market view and trading context

Hikma is listed on the London Stock Exchange, and its shares trade in sterling as a constituent of the FTSE 100 index, giving the stock broad visibility among institutional and retail investors who track the benchmark.

Portfolio disclosures such as the top holdings update from The Merchants Trust, which listed Hikma Pharmaceuticals as a position representing 2.68 percent of that trust's assets as of a recent report, highlight that long-term investment vehicles continue to hold the stock as part of diversified portfolios linked to UK equities, as reported by Investegate on September 14, 2026.

Stock price and investor perspective

At the close on September 11, 2026, Hikma stock finished at EUR 21.40 on its London trading venue, up 1.9 percent from the prior session and within a EUR 20.90 to EUR 21.45 intraday range, according to Ad-hoc-news.

This move left the closing price just EUR 0.05 below the session high, suggesting that buyers were willing to pay close to the top of the day's range as filings for the epinephrine nasal spray advanced and the broader FTSE 100 index also closed higher on September 11, 2026.